Right ventricular failure: A novel era of targeted therapy

被引：19

作者：

Banerjee D. ^{[1
]}

Haddad F. ^{[1
]}

Zamanian R.T. ^{[2
]}

Nagendran J.

机构：

[1] Division of Cardiovascular Medicine, School of Medicine, Stanford University, Stanford, CA 94305

[2] Division of Pulmonary and Critical Care Medicine, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford School of Medicine, Stanford, CA 94305, 300 Pasteur Drive

来源：

Current Heart Failure Reports | 2010年 / 7卷 / 4期

关键词：

Biomarkers; Heart failure; Hypertrophy; Right ventricle; Therapy;

D O I：

10.1007/s11897-010-0031-7

中图分类号：

学科分类号：

摘要：

There now is strong evidence to recognize the pivotal role of the right ventricle (RV) in heart disease and to establish it as a unique and separate entity than the left ventricle (LV). Here, we summarize the differences between the two ventricles, the diagnosis of RV failure, and the management of acute and chronic RV failure. We review the indices derived by echocardiography used to measure RV function, and novel biomarkers that may play a role diagnosing and prognosticating in RV-specific disease. There are new novel therapies that specifically target the RV in disease. For example, phosphodiesterase type 5 inhibitors improve contractility of the hypertrophied RV while sparing the normal LV in pulmonary arterial hypertension. The metabolism of the hypertrophied RV is another area for therapeutic exploitation by metabolic modulation. We also suggest future potential molecular targets that may be unique to the RV because they are upregulated in RV hypertrophy greater than in LV hypertrophy. © 2010 Springer Science+Business Media, LLC.

引用

页码：202 / 211

页数：9

共 91 条

[1]

Bangalore S., Yao S.-S., Chaudhry F.A., Role of Right Ventricular Wall Motion Abnormalities in Risk Stratification and Prognosis of Patients Referred for Stress Echocardiography, Journal of the American College of Cardiology, 50, 20, pp. 1981-1989, (2007)

[2]

De Groote P., Millaire A., Foucher-Hossein C., Nugue O., Marchandise X., Ducloux G., Lablanche J.-M., Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure, Journal of the American College of Cardiology, 32, 4, pp. 948-954, (1998)

[3]

Ghio S., Gavazzi A., Campana C., Inserra C., Klersy C., Sebastiani R., Arbustini E., Recusani F., Tavazzi L., Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure, Journal of the American College of Cardiology, 37, 1, pp. 183-188, (2001)

[4]

Meyer P., Filippatos G.S., Ahmed M.I., Et al., Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure, Circulation, 121, pp. 252-258, (2010)

[5]

Forfia P.R., Fisher M.R., Mathai S.C., Housten-Harris T., Hemnes A.R., Borlaug B.A., Chamera E., Corretti M.C., Champion H.C., Abraham T.P., Girgis R.E., Hassoun P.M., Tricuspid annular displacement predicts survival in pulmonary hypertension, American Journal of Respiratory and Critical Care Medicine, 174, 9, pp. 1034-1041, (2006)

[6]

Goldhaber S.Z., Visani L., De Rosa M., Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER), Lancet, 353, 9162, pp. 1386-1389, (1999)

[7]

D'Alonzo G.E., Barst R.J., Ayres S.M., Et al., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, pp. 343-349, (1991)

[8]

Goldstein J.A., Pathophysiology and management of right heart ischemia, Journal of the American College of Cardiology, 40, 5, pp. 841-853, (2002)

[9]

Califf R.M., Adams K.F., McKenna W.J., Gheorghiade M., Uretsky B.F., McNulty S.E., Darius H., Schulman K., Zannad F., Handberg-Thurmond E., Harrell Jr. F.E., Wheeler W., Soler-Soler J., Swedberg K., A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST), American Heart Journal, 134, 1, pp. 44-54, (1997)

[10]

Yutzey K.E., Kirby M.L., Wherefore heart thou? Embryonic origins of cardiogenic mesoderm, Developmental Dynamics, 223, 3, pp. 307-320, (2002)

← 1 2 3 4 5 6 7 8 9 10 →